ミズーリ州における乳がんの臨床試験
ミズーリ州内の拠点で、乳がんに関する75件の研究が参加者を募集しています。
ミズーリ州内の都市
- St. Louis64件の研究
- Kansas City34件の研究
- Springfield10件の研究
- Lee's Summit7件の研究
- Saint Joseph7件の研究
- Columbia6件の研究
- O'Fallon6件の研究
- Joplin4件の研究
- Cape Girardeau4件の研究
- Rolla3件の研究
公式研究テキスト（英語）
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
- HCA Midwest Division, Kansas City
被験者募集中第3相
18歳〜100歳 · 全性別 · 2026/10/02更新 · NCT05827081Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mercy Oncology and Hematology - Clayton-Clarkson, Ballwin
- Central Care Cancer Center - Bolivar, Bolivar
- Cox Cancer Center Branson, Branson
- 他21件
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Washington University, School of Medicine, St Louis
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06172478Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- St. Lukes Hospital of Kansas City, Kansas City
- Washington University School of Medicine, St Louis
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06625775A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
- Missouri Cancer Associates, Columbia
- Saint Luke's Cancer Institute, Kansas City
- Oncology Hematology Associates, Springfield
- 他1件
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06369285An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
- Washington University in St Louis, St Louis
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07222267A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Saint Luke's Cancer Institute ( Site 0059), Kansas City
- Washington University Siteman Cancer Center ( Site 0031), St Louis
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06966700A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Saint Luke's Cancer Institute ( Site 0027), Kansas City
- Washington University School of Medicine ( Site 0076), St Louis
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06312176A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, St Louis
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06103864ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- Washington University School of Medicine- Siteman Cancer Center, St Louis
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07007559A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- Local Institution - 0140, St Louis
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/23更新 · NCT06618287Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Clinical Trial Site, Kansas City
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/23更新 · NCT07085767Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
- Mercy Health - Sindelar Cancer Center, St Louis
- Mercy Health - Pratt Cancer Center, St Louis
被験者募集中
18歳以上 · 全性別 · 2026/09/23更新 · NCT07214532Cognitive Rehabilitation Following Breast Cancer Treatment
- University of Missouri, Columbia
被験者募集中
20歳〜75歳 · 女性 · 2026/09/22更新 · NCT06545045A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Saint Luke's Cancer Institute, Kansas City
- Oncology Hematology Associates, Springfield
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07174336A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Washington University, St Louis
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07114601A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- Washington University School of Medicine, St Louis
被験者募集中第2相
18歳以上 · 女性 · 2026/09/22更新 · NCT07287098A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Washington University School of Medicine in St. Louis, St Louis
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07213791ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- Saint Luke's Hospital of Kansas City, Kansas City
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/17更新 · NCT07173751A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- Washington Univ. School of Medicine, St Louis
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/17更新 · NCT07109726A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
- Saint Luke's Hospital of Kansas City, Kansas City
- Washington University School of Medicine, St Louis
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/17更新 · NCT06827236Precision Supplemental Imaging in Women With Dense Breasts
- Washington University School of Medicine, St Louis
被験者募集中健康なボランティア歓迎
25歳〜55歳 · 女性 · 2026/09/16更新 · NCT07277738A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
- Siteman Cancer Center, St Louis
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/15更新 · NCT06492616A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Research Site, St Louis
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/11更新 · NCT05123482A Phase 1/1b Study of IAM1363 in HER2 Cancers
- Saint Luke's Cancer Institute, Kansas City
- Washington University School of Medicine, St Louis
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/09更新 · NCT06253871A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
- Washington University School of Medicine, St Louis
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/09更新 · NCT06440005A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
- Washington University Medical School, St Louis
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/08更新 · NCT05307705A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
- Washington University Siteman Cancer Center, St Louis
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/08更新 · NCT07100106To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
- HCA Midwest Division, Kansas City
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/04更新 · NCT07368998Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Washington University School of Medicine- Siteman Cancer Center, St Louis
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/03更新 · NCT06982521Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
- Oncology Hematology Associates, Springfield
被験者募集中観察研究
18歳〜99歳 · 全性別 · 2026/09/03更新 · NCT07211178A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- HCA Midwest Health, Kansas City
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/03更新 · NCT06790693Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women
- Washington University School of Medicine, St Louis
被験者募集中観察研究
18歳〜50歳 · 女性 · 2026/09/02更新 · NCT06904365The Vanguard Study: Testing a New Way to Screen for Cancer
- Saint Luke's Hospital of Kansas City, Kansas City
- Washington University School of Medicine, St Louis
被験者募集中健康なボランティア歓迎
45歳〜75歳 · 全性別 · 2026/09/02更新 · NCT06995898Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Mercy Oncology and Hematology - Clayton-Clarkson, Ballwin
- Central Care Cancer Center - Bolivar, Bolivar
- Cox Cancer Center Branson, Branson
- 他29件
被験者募集中第3相
18歳〜60歳 · 女性 · 2026/09/02更新 · NCT05879926A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- Washington University, St Louis
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/28更新 · NCT07029399Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
- WA Uni School Of Med, St Louis
被験者募集中第1/2相
18歳〜100歳 · 全性別 · 2026/08/27更新 · NCT06726148A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
- Washington University School of Medicine - Siteman Cancer Center, St Louis
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/26更新 · NCT07383506A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- Washington University, Siteman Cancer Center, St Louis
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/21更新 · NCT06774963Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry
- Universtiy Health, Kansas City
- KCCC South, Kansas City
- Research Medical Center, Kansas City
- 他2件
被験者募集中観察研究健康なボランティア歓迎
全年齢 · 全性別 · 2026/08/18更新 · NCT02302742ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。